JP7854001B2 - α１－アンチトリプシン欠乏症の処置のための組成物およびそれらの使用 - Google Patents

α１－アンチトリプシン欠乏症の処置のための組成物およびそれらの使用

Info

Publication number
JP7854001B2
JP7854001B2 JP2023577946A JP2023577946A JP7854001B2 JP 7854001 B2 JP7854001 B2 JP 7854001B2 JP 2023577946 A JP2023577946 A JP 2023577946A JP 2023577946 A JP2023577946 A JP 2023577946A JP 7854001 B2 JP7854001 B2 JP 7854001B2
Authority
JP
Japan
Prior art keywords
a1at
piperidine
sulfonyl
carboxylic acid
trifluoromethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023577946A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024523406A (ja
JP2024523406A5 (https=
Inventor
ナイジェル ラムズデン，
デイビッド ジョン フォックス，
ジェイムズ アンドリュー ハンティントン，
Original Assignee
センテッサ ファーマシューティカルズ （ユーケー） リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by センテッサ ファーマシューティカルズ （ユーケー） リミテッド filed Critical センテッサ ファーマシューティカルズ （ユーケー） リミテッド
Publication of JP2024523406A publication Critical patent/JP2024523406A/ja
Publication of JP2024523406A5 publication Critical patent/JP2024523406A5/ja
Application granted granted Critical
Publication of JP7854001B2 publication Critical patent/JP7854001B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2023577946A 2021-06-15 2022-06-15 α１－アンチトリプシン欠乏症の処置のための組成物およびそれらの使用 Active JP7854001B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2108523.8A GB202108523D0 (en) 2021-06-15 2021-06-15 Compositions and their use for the treatment of alpha1-antitrypsin deficiency
GB2108523.8 2021-06-15
PCT/GB2022/051502 WO2022263816A1 (en) 2021-06-15 2022-06-15 COMPOSITIONS AND THEIR USE FOR THE TREATMENT OF α1-ANTITRYPSIN DEFICIENCY

Publications (3)

Publication Number Publication Date
JP2024523406A JP2024523406A (ja) 2024-06-28
JP2024523406A5 JP2024523406A5 (https=) 2025-06-20
JP7854001B2 true JP7854001B2 (ja) 2026-04-30

Family

ID=76954605

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023577946A Active JP7854001B2 (ja) 2021-06-15 2022-06-15 α１－アンチトリプシン欠乏症の処置のための組成物およびそれらの使用

Country Status (12)

Country Link
US (1) US20240197707A1 (https=)
EP (1) EP4355328A1 (https=)
JP (1) JP7854001B2 (https=)
KR (1) KR20240027693A (https=)
CN (1) CN117794538A (https=)
AU (1) AU2022295130A1 (https=)
BR (1) BR112023026510A2 (https=)
CA (1) CA3223130A1 (https=)
GB (1) GB202108523D0 (https=)
IL (1) IL309355A (https=)
MX (1) MX2023015398A (https=)
WO (1) WO2022263816A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201918410D0 (en) 2019-12-13 2020-01-29 Z Factor Ltd Compounds and their use for the treatment of alpha1-antitrypsin deficiency

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7708760B2 (ja) 2019-12-13 2025-07-15 センテッサ ファーマシューティカルズ （ユーケー） リミテッド 化合物及びα１－アンチトリプシン欠損症の治療のためのそれらの使用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2071621C (en) 1991-06-19 1996-08-06 Ahihiko Hosoda Aldehyde derivatives
WO2008143633A2 (en) 2007-01-10 2008-11-27 University Of Florida Compounds and methods for treatment of alpha-1 antitrypsin deficiency
US8258158B2 (en) 2009-09-11 2012-09-04 Hoffmann-La Roche Inc. HSL inhibitors useful in the treatment of diabetes
WO2012097371A2 (en) 2011-01-14 2012-07-19 The Regents Of The University Of California Chemical inhibitors of cholesterol biosynthesis and venous angiogenesis
MX2020013853A (es) 2018-06-22 2021-05-27 Ucl Business Ltd Compuestos innovadores.
CA3114672A1 (en) 2018-10-05 2020-04-23 Vertex Pharmaceuticals Incorporated Modulators of alpha-1 antitrypsin
US11884672B2 (en) 2019-05-14 2024-01-30 Vertex Pharmaceuticals Incorporated Modulators of alpha-1 antitrypsin

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7708760B2 (ja) 2019-12-13 2025-07-15 センテッサ ファーマシューティカルズ （ユーケー） リミテッド 化合物及びα１－アンチトリプシン欠損症の治療のためのそれらの使用

Also Published As

Publication number Publication date
MX2023015398A (es) 2024-04-29
CN117794538A (zh) 2024-03-29
JP2024523406A (ja) 2024-06-28
EP4355328A1 (en) 2024-04-24
WO2022263816A1 (en) 2022-12-22
IL309355A (en) 2024-02-01
GB202108523D0 (en) 2021-07-28
US20240197707A1 (en) 2024-06-20
KR20240027693A (ko) 2024-03-04
CA3223130A1 (en) 2022-12-22
BR112023026510A2 (pt) 2024-03-05
AU2022295130A1 (en) 2024-01-18

Similar Documents

Publication Publication Date Title
JP7487203B2 (ja) α１－アンチトリプシン欠乏症の治療のための化合物とそれらの使用
US12611402B2 (en) Compounds and their use for the treatment of ALPHA1-antitrypsin deficiency
US12286402B2 (en) Compounds and their use for the treatment of alpha1-antitrypsin deficiency
JP7854001B2 (ja) α１－アンチトリプシン欠乏症の処置のための組成物およびそれらの使用
US20230102488A1 (en) Compounds and their use for the treatment of alpha1-antitrypsin deficiency
US20230093755A1 (en) Compounds and their use for the treatment of alpha1-antitrypsin deficiency
HK40079913A (en) Compounds and their use for the treatment of alpha1-antitrypsin deficiency
HK40079913B (en) Compounds and their use for the treatment of alpha1-antitrypsin deficiency

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250612

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250612

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260317

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260326

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260417